Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
about
Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopyRegression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results.Characterizing white matter with magnetization transfer and T(2).Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets.Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group.Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials.Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?Subtraction MR images in a multiple sclerosis multicenter clinical trial setting.Interferon-beta1a: a once-weekly immunomodulatory treatment for patients with multiple sclerosis.The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study.Physicians, subsequence and consequence.Magnetisation transfer ratio of normal brain white matter: a normative database spanning four decades of lifeNuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosisRelaxation time mapping in multiple sclerosis.Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.Drug treatment of multiple sclerosisTherapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosisProbiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 studyThe NEO-FFI in Multiple Sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports.Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted imagesChanges in the normal appearing brain tissue and cognitive impairment in multiple sclerosis.Overall Memory Impairment Identification with Mathematical Modeling of the CVLT-II Learning Curve in Multiple SclerosisMRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort.An algorithm for automatic segmentation and classification of magnetic resonance brain imagesSurvey of the distribution of lesion size in multiple sclerosis: implication for the measurement of total lesion load.Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences.Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination.Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques.Update on the relationships between neuropsychological dysfunction and structural MRI in multiple sclerosis.Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force.More immunotherapy for multiple sclerosis.Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosisLateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MR spectroscopy study.
P2860
Q24800569-0CC30478-2FA6-4D12-99EE-BCE8E9CFAC46Q26998513-A9442B4C-6CCE-4D89-BC7F-E72C28E8F24EQ30573085-421B8C33-30EC-4E8F-995C-EB58CBE1847EQ30584744-B803C1F8-8628-497F-9978-D12A8C9FFDB6Q30585635-D457362C-36FA-401F-BDF0-001E3A16513AQ30640097-D87ECB78-6714-4924-9F48-E14B0BB24E5CQ30691743-BC1D8F4E-CB2C-41DC-BC10-9A977314CCECQ30816299-43D1D7E8-D18E-4862-9F61-1FBC52E09A7EQ30953733-0C0FFB88-C657-4E36-BFA9-6AF74E15A67AQ31037055-9A99C90A-5E13-4C53-897D-FE2B9B1D3E78Q33289264-5C3171BC-497E-4460-8FDC-5C3417D9EC05Q33387539-DEBC9197-37AC-46AD-B892-076781257C48Q33579409-E4925381-93F1-4E95-9260-90B6200E385BQ33624724-D4B03874-8602-4DF4-BDCA-C84DBA16B085Q33712704-6BEA8473-DF25-490E-B0D5-E575F0D463D7Q33714962-F801757E-55DC-49A7-85B3-DB399271DD27Q33798244-7A9CB232-F11C-40C1-B6D9-77D7D4D22700Q33837306-24E94B49-AC24-47BF-B554-7C87332DDDA5Q33899917-0E459B04-D6BA-4456-9D2C-DCA525732DF8Q34007633-2152FB4E-188C-441F-BC50-FC6CCC528240Q34064209-69834711-0F3C-4515-A878-359A8B38504FQ34123689-2EA5ADAB-E097-40B6-9258-A2883F8ED93EQ34168414-F626DD17-057C-490D-92D4-EA7DE39706FEQ34192249-89409A5C-CEB8-464B-8EE6-DD1BCC9A9AC2Q35454159-6CB85311-8506-4B56-9598-842F140F3E6CQ35455319-C752707E-A1EE-4F99-A363-AE83BBAF8319Q36055751-11E445AC-88CD-4F24-876A-CA3B2EB98E4AQ36141526-694A173E-F8AF-489E-9EDD-2B2ACFBD1C32Q36262820-0C34BC23-535F-4055-81CA-D2206DE8B6EDQ36317293-44C49FE3-3238-4921-8A4E-92E53D10C86AQ36317642-E013BC61-D12C-4119-BA47-D186B006AFB1Q36317785-7C365618-A2EF-4A5D-A949-F6A4D23E9F0AQ36317863-D3AB4FBB-9CB8-47B9-9730-219E0F57FADFQ36318391-D9CB0996-7B85-4B48-911D-7A9267E71C4BQ36419562-31F8FA4D-2447-4055-80F8-9485606223A7Q36814514-4ED13D5A-BD2D-4EFA-B4E3-9F66AA2E24C7Q36887909-1FC6AA9F-201D-4A55-B211-16393EF87E79Q36896700-FEB1B15F-3E6F-4E38-B89B-8488E9133C80Q37381504-619067CA-E14D-45C0-99CF-091522DD35F6Q37415382-FC73618C-5BF7-4A50-823E-9857B22FF6DC
P2860
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Guidelines for the use of magn ...... ational MS Society Task Force.
@ast
Guidelines for the use of magn ...... ational MS Society Task Force.
@en
type
label
Guidelines for the use of magn ...... ational MS Society Task Force.
@ast
Guidelines for the use of magn ...... ational MS Society Task Force.
@en
prefLabel
Guidelines for the use of magn ...... ational MS Society Task Force.
@ast
Guidelines for the use of magn ...... ational MS Society Task Force.
@en
P2093
P2860
P356
P1433
P1476
Guidelines for the use of magn ...... National MS Society Task Force
@en
P2093
Reingold SC
P2860
P356
10.1002/ANA.410390104
P577
1996-01-01T00:00:00Z